Mufemilast

Mufemilast
Clinical data
Other names	Hemay005
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[5-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,6-dioxothieno[3,4-c]pyrrol-3-yl]acetamide;
CAS Number	1255909-03-5;
PubChem CID	137355584;
ChemSpider	115010424;
UNII	4QX9BK9E7P;
ChEMBL	ChEMBL5095240;
Chemical and physical data
Formula	C20H22N2O7S2
Molar mass	466.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=CSC(=C3C2=O)NC(=O)C)OC;
	InChI InChI=1S/C20H22N2O7S2/c1-5-29-16-8-12(6-7-15(16)28-3)14(10-31(4,26)27)22-19(24)13-9-30-18(21-11(2)23)17(13)20(22)25/h6-9,14H,5,10H2,1-4H3,(H,21,23)/t14-/m1/s1; Key:PRSNGWLHNWGOKD-CQSZACIVSA-N;

Mufemilast (Hemay005) is a small-molecule inhibitor of phosphodiesterase 4. It is developed by Hemay Pharmaceutical for psoriasis.^[1]^[2]^[3]

References

^ Liu, Xuemei; Chen, Rui; Zeng, Guanghuai; Gao, Ying; Liu, Xiuping; Zhang, Donglei; Hu, Pei; Wang, Hongyun; Jiang, Ji (1 June 2018). "Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study". Bioanalysis. 10 (11): 863–875. doi:10.4155/bio-2018-0004. ISSN 1757-6199. PMID 29863892. S2CID 46929693.
^ Tomar, Yashika; Gorantla, Srividya; Singhvi, Gautam (February 2023). "Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches". Drug Discovery Today. 28 (2) 103465. doi:10.1016/j.drudis.2022.103465. PMID 36481585. S2CID 254304811.
^ Claudia, Cervantes-Durán; María-Elena, Velázquez-Hernández; Josué, Valentín-Escalera; María-Carmen, Bartolomé-Camacho; Alain-Raimundo, Rodríguez-Orozco; Martha-Estrella, García-Pérez (November 2020). "Small molecules under development for psoriasis: on the road to the individualized therapies". Archives of Dermatological Research. 312 (9): 611–627. doi:10.1007/s00403-020-02056-3. PMID 32172339. S2CID 212706837.